Composition comprising lactiplantibacillus plantarum MTY101 for improving muscle function and preventing or ameliorating muscle diseases
Lactiplantibacillus plantarum MTY101 addresses the lack of a cure for sarcopenia by promoting muscle differentiation and synthesis, inhibiting breakdown, and enhancing muscle strength, providing a potential therapeutic solution for muscle weakness and atrophy.
Patent Information
- Application Number
- PCT/KR2026/005797
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-04-30
- Publication Date
- 2026-11-12
AI Technical Summary
There is currently no effective cure for sarcopenia, a disease characterized by muscle loss and weakness, which affects a significant portion of the aging population and increases the risk of metabolic syndrome, osteoporosis, fractures, and mortality.
The use of Lactiplantibacillus plantarum MTY101 strain, its culture medium, concentrate, lysate, or dried product to promote muscle differentiation, inhibit muscle breakdown, and enhance muscle synthesis, thereby preventing or treating muscle weakness, loss, or atrophy.
Lactiplantibacillus plantarum MTY101 effectively inhibits muscle breakdown while promoting muscle synthesis and strength, offering potential therapeutic benefits for muscle diseases such as sarcopenia, muscular atrophy, and other muscle-related conditions.
Smart Images

Figure KR2026005797_12112026_PF_FP_ABST
Abstract
Description
Composition for improving muscle function, preventing or improving muscle diseases comprising Lactipiranti Bacillus plantarum MTY101
[0001] The present invention relates to the use of Lactiplantibacillus plantarum MTY101 for the prevention, improvement, or treatment of muscle weakness, muscle loss, or muscle atrophy; and for the use of strengthening muscle function.
[0002] Muscle accounts for approximately 40–50% of a person's body weight. Around the age of 50, the rate of muscle protein synthesis within muscle cells slows down compared to the rate of breakdown, causing muscles to begin degenerating rapidly and making individuals susceptible to muscle loss diseases. Sarcopenia, a disease characterized by a gradual decline in muscle mass and strength, primarily manifests as muscle loss and weakness. The significant reduction in physical activity not only impairs mental health but also lowers life satisfaction; furthermore, it can lead to easy injuries even during simple daily activities, potentially resulting in serious complications. While sarcopenia primarily affects the elderly, it is now occurring across all generations. Currently in Korea, one in six people is aged 65 or older, and the number of sarcopenia patients is on the rise due to the aging population. Recently, muscle loss in the elderly has been recognized as a disease rather than natural aging, and it is already being managed with a disease code assigned in the United States (2016), the WHO (2017), and Japan (2018), and a disease code was also assigned in Korea in 2021. It is known that in the presence of sarcopenia, the risk of death increases fivefold due to metabolic syndrome, including obesity, diabetes, and heart disease, as well as osteoporosis and fractures. Although a disease code has been assigned for sarcopenia, there is currently no cure available.
[0003] Accordingly, while researching the prevention, improvement, or treatment of muscle strength loss, muscle loss, or muscle atrophy, the inventors isolated Lactiplantibacillus plantarum MTY101, which promotes muscle differentiation and formation. Furthermore, by confirming that the isolated strain inhibits muscle breakdown while simultaneously promoting muscle synthesis and muscle strength, the present invention was completed.
[0004] Accordingly, the object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of diseases caused by muscle weakness, muscle loss, or muscle atrophy, comprising the strain Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.
[0005] Another object of the present invention is to provide a composition for preventing or improving muscle weakness, muscle loss, or muscle atrophy comprising the strain Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.
[0006] Another objective of the present invention is to provide a composition for muscle enhancement and strength improvement comprising the strain Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.
[0007] Another objective of the present invention is to provide a method for preventing or treating a disease caused by muscle weakness, muscle loss, or muscle atrophy, comprising the step of administering the strain of Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof to an individual in need thereof.
[0008] Another object of the present invention is to provide a use of the Lactiplantibacillus plantarum MTY101 strain (accession number: KCTC15786BP), its culture medium, its concentrate, its lysate, its dried form, or a combination thereof, for the manufacture of a drug for the prevention or treatment of diseases caused by muscle loss, muscle atrophy, or muscle weakness.
[0009] To achieve the above objective, the present invention provides a pharmaceutical composition for the prevention or treatment of diseases caused by muscle weakness, muscle loss, or muscle atrophy, comprising the strain Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.
[0010] In addition, the present invention provides a food composition for preventing or improving muscle strength loss, muscle loss, or muscle atrophy comprising the strain Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the mash thereof, the dried product thereof, or a combination thereof.
[0011] In addition, the present invention provides a health functional food composition for the prevention or improvement of muscle strength loss, muscle loss, or muscle atrophy comprising the strain Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.
[0012] In addition, the present invention provides a feed composition for preventing or improving muscle loss, muscle loss, or muscle atrophy comprising the strain Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the crushed product thereof, the dried product thereof, or a combination thereof.
[0013] In addition, the present invention provides a composition for muscle enhancement comprising the Lactiplantibacillus plantarum MTY101 strain (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.
[0014] In addition, the present invention provides a composition for strengthening muscle strength comprising the Lactiplantibacillus plantarum MTY101 strain (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the pulverized product thereof, the dried product thereof, or a combination thereof.
[0015] In addition, the present invention provides a method for preventing or treating a disease caused by muscle weakness, muscle loss, or muscle atrophy, comprising the step of administering the strain of Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof to an individual in need thereof.
[0016] In addition, the present invention provides the use of the Lactiplantibacillus plantarum MTY101 strain (accession number: KCTC15786BP), its culture medium, its concentrate, its lysate, its dried form, or a combination thereof, for the manufacture of a drug for the prevention or treatment of diseases caused by muscle loss, muscle atrophy, or muscle weakness.
[0017] The Lactiplantibacillus plantarum MTY101 strain of the present invention has the effect of preventing muscle loss, muscle atrophy, or muscle weakness and enhancing muscle function. The Lactiplantibacillus plantarum MTY101 strain of the present invention can be utilized in various ways in the field of treating muscle loss, muscle atrophy, or muscle weakness; and in the field of enhancing muscle function.
[0018] Figure 1 is a figure showing the results of analyzing the phylogenetic tree (left) and ANI (right) of Lactobacillus plantarum MTY101 (indicated by the box).
[0019] Figure 2 shows the results of analyzing the YY1-promoter activity inhibitory function of Lactibacillus plantarum MTY101 lactic acid bacteria culture medium using the HTS (High-throughput screening); PHF20-pYY1-Gluc assay to evaluate muscle differentiation in C2C12 myoblasts.
[0020] Figure 3 shows the results of analyzing the expression of biomarkers for muscle degradation (Atrogin-1, MuRF-1) and muscle synthesis (AKT phosphorylation: P-AKT) at the protein (a) and mRNA (b) levels after treating a dexamethasone-induced muscle atrophy C2C12-cell model with a culture of Lactibacillus plantarum MTY101 for 24 hours.
[0021] Figure 4a shows the results of analyzing cell viability after treating C2C12 myoblasts with a culture of Lactobacillus plantarum MTY101 for 24 hours.
[0022] Figure 4b shows the results of analyzing cell viability after treating a dexamethasone-induced muscular atrophy C2C12-cell model with Lactibacillus plantarum MTY101 culture medium and dexamethasone for 24 hours.
[0023] Figure 5 shows the results of analyzing myotube formation through MyHC (Myosin heavy chain) immunofluorescence staining after differentiating C2C12 myoblasts for 3 days in a muscle differentiation medium supplemented with Lactibacillus plantarum MTY101 lactic acid bacteria culture medium.
[0024] Figure 6 shows the results of measuring body weight (a) and grip strength (b) during the administration period of Lactibacillus plantarum MTY101 lactic acid bacteria (live bacteria) in a mouse model of dexamethasone-induced muscular atrophy.
[0025] Figure 7 shows the total muscle mass (a), right hind leg muscle mass (b), results of measuring right hind leg muscle mass before and after administration (c), and results of tissue staining of the right hind leg tibialis muscle (d) and analysis of its cross-section area (e) after the administration of Lactibacillus plantarum MTY101 (live bacteria) in dexamethasone-induced muscle atrophy mice.
[0026] The present invention will be described in detail below.
[0027] According to another aspect of the present invention, the present invention provides a composition for preventing or improving muscle weakness, muscle loss, or muscle atrophy comprising the strain Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof. The composition for preventing or improving muscle weakness, muscle loss, or muscle atrophy may be a food composition, a health functional food composition, or a feed composition.
[0028] The inventors selected strains with activity promoting muscle differentiation and formation from a lactic acid bacteria culture library using a muscle differentiation evaluation HTS system in the same manner as Example 1 described below. The selected strain, Lactiplantibacillus plantarum MTY101, was deposited with the Biological Resource Center (Jeongeup-si, Jeollabuk-do, Korea) on March 19, 2025, in accordance with the Treaty of Budapest, and was assigned accession number KCTC15786BP.
[0029] Experiments have confirmed that the selected Lactiplantibacillus plantarum MTY101 not only has no cytotoxicity but also inhibits muscle breakdown while simultaneously promoting muscle synthesis and improving muscle strength. Therefore, the Lactiplantibacillus plantarum MTY101 of the present invention can be utilized in various fields, including the treatment of muscle weakness diseases; fields related to increasing muscle strength; the treatment of muscle loss diseases; fields related to increasing muscle; and fields related to strengthening muscle function.
[0030] In a specific embodiment of the present invention, the strain preferably has one or more activities selected from the group consisting of promoting differentiation of muscle cells, inhibiting death of muscle cells, improving muscle strength, improving exercise performance, and increasing mineral content in the body, but the scope of the present invention is not limited thereto.
[0031] In the present invention, the culture medium refers to a medium containing by-products generated through the intake of nutrients and metabolism of a strain and the strain itself, obtained by culturing the strain in a medium; specifically, it may refer to a culture medium or culture product of the strain. Furthermore, a concentrated or diluted solution of the culture medium, a dried or freeze-dried product obtained by drying the culture medium, a modified or purified product of the culture medium, a crushed product obtained by crushing the culture medium, or a mixture thereof may also be included as an active ingredient in the composition of the present invention.
[0032] In a specific embodiment of the present invention, the strain may be included in the form of a live cell, a dead cell, or a combination thereof.
[0033] In the present invention, the cell refers to the strain of the present invention itself and includes the strain itself or a strain isolated from a culture medium by culturing said strain, and may be a live cell or a dead cell. The cell may be obtained by centrifuging the culture medium and taking the portion that settles to the bottom layer, or by letting it sit for a certain period of time and removing the liquid from the top, as it sinks to the bottom layer of the culture medium due to gravity.
[0034] In a specific embodiment of the present invention, the prevention or improvement of muscle strength reduction, muscle loss, or muscle atrophy may be muscle strengthening, muscle strength improvement, muscle enhancement, promotion of muscle differentiation, or muscle regeneration.
[0035] In the present invention, muscle differentiation refers to the process in which mononuclear myoblasts form multinuclear myotubes through fusion, and refers to the induction of such a process. Cells in the differentiation stage forming myotubes are identified through the expression of markers such as Pax7, MyoD, and MyoG. By promoting the differentiation of myoblasts, the number of muscle cells increases, which can ultimately lead to an increase in muscle mass in the individual.
[0036] In the present invention, muscle regeneration refers to the ability of a damaged muscle to recover to a normal state. The muscle regeneration may be an effect resulting from the promotion of muscle cell differentiation, which increases the absolute amount of muscle cells, or from an increase in the diameter of individual muscle canals.
[0037] Foods according to the present invention include, for example, various types of food, beverages, chewing gum, tea, vitamin complexes, functional foods, etc. In addition, foods include, but are not limited to, special nutritional foods (e.g., infant formula, baby food, etc.), processed meat products, fish products, tofu products, jelly products, noodles (e.g., ramen, noodles, etc.), bread products, health supplements, seasoning foods (e.g., soy sauce, soybean paste, red pepper paste, mixed sauce, etc.), sauces, confectionery products (e.g., snacks), candies, chocolates, chewing gum, ice cream, dairy products (e.g., fermented milk, cheese, etc.), other processed foods, kimchi, pickled foods (various types of kimchi, pickled vegetables, etc.), beverages (e.g., fruit beverages, vegetable beverages, soy milk, fermented beverages, etc.), natural seasonings (e.g., ramen soup, etc.), and food additives. The above foods, beverages, or food additives may be manufactured by conventional manufacturing methods.
[0038] In the present invention, a health functional food refers to a group of foods to which added value has been imparted by utilizing physical, biochemical, or biotechnological methods to enable the function of the food to act or manifest for a specific purpose, or to a food processed by designing it to sufficiently express in the body the in vivo regulatory functions regarding the regulation of biological defense rhythms, disease prevention, and recovery possessed by the food composition. For the purposes of the present invention, the health functional food refers to one intended to promote muscle strength enhancement, muscle augmentation, muscle differentiation, or muscle regeneration activity.
[0039] When the composition of the present invention is used as an additive to food or health functional food, the composition may be added as is or used together with other ingredients, and may be used appropriately according to conventional methods. The amount of the active ingredient can be appropriately determined according to the purpose of use. Generally, when manufacturing food or beverages, the composition of the present invention may be added to the raw material in an amount preferably 50 parts by weight or less, more preferably 25 parts by weight or less. However, in the case of long-term consumption for the purpose of health control and hygiene, the above amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount greater than the above range.
[0040] The food or health functional food composition of the present invention may contain a food-grade carrier, or various conventional flavoring agents or natural carbohydrates as additional ingredients. Examples of the above-mentioned natural carbohydrates include monosaccharides, e.g., glucose, fructose, etc.; disaccharides, e.g., maltose, sucrose, etc.; polysaccharides, e.g., dextrin, cyclodextrin, etc., and conventional sugars, and sugar alcohols such as xylitol, sorbitol, erythritol, etc. The above-mentioned flavoring agents may advantageously include natural flavoring agents (taumatin), stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.), and synthetic flavoring agents (saccharin, aspartame, etc.).
[0041] In the present invention, the term "feed" refers to any natural or artificial meal, single-meal food, etc., consumed by an animal, or the components of said single-meal food. The feed composition according to the present invention can be prepared in various forms of feed known in the art, and preferably may include concentrated feed, roughage, and / or special feed, but is not limited thereto.
[0042] The feed composition of the present invention may be a feed additive composition. The feed additive composition includes a substance added to the feed for the purpose of various effects, such as alleviating disease symptoms in animals, supplementing nutrients and preventing weight loss, improving the digestibility and utilization of fiber in the feed, improving milk quality, preventing reproductive disorders and improving conception rates, and preventing high-temperature stress during the summer.
[0043] The feed additive composition of the present invention corresponds to an auxiliary feed under the Feed Management Act and may additionally include mineral preparations such as sodium bicarbonate, bentonite, magnesium oxide, and complex minerals; mineral preparations that are trace minerals such as zinc, copper, cobalt, and selenium; vitamin preparations such as carotene, vitamins A, E, nicotinic acid, and vitamin B complex; protected amino acid preparations such as methionine and lysine; protected fatty acid preparations such as calcium salts of fatty acids; probiotics (lactic acid bacteria preparations); probiotics such as yeast cultures and mold fermentation products; yeast preparations, etc.
[0044] Among the above feeds, concentrated feeds include, but are not limited to, seed grains such as wheat, oats, and corn; bran, which is a byproduct obtained by refining grains and includes rice bran, wheat bran, and barley bran; oilseed meal, which is a byproduct obtained by extracting oil from soybeans, rapeseed, sesame, flaxseed, and coconut; residues such as residual starch, which is the main component of starch residue remaining after removing starch from sweet potatoes, potatoes, etc.; fish meal, fish residue; fish soluble, which is a concentrated fresh liquid obtained from fish; meat meal; blood meal; feather meal; skim milk powder; dried whey, which is the residue obtained when making cheese from milk or casein from skim milk; yeast, Chlorella, and seaweed.
[0045] Among the above feeds, roughage includes raw grass feeds such as wild grass, pasture grass, and green cuts; root vegetables such as feed turnips, feed beets, and a type of turnip called lutea bearger; silage, which is a storage feed made by filling a silo with raw grass, green cut crops, and grains and fermenting them with lactic acid; hay made by cutting and drying wild grass and pasture grass; straw of livestock breeding crops; and leaves of legumes, but is not limited thereto. Special feeds include mineral feeds such as oyster shells and rock salt; urea feeds such as urea or its derivatives such as diuretic isobutane; feed additives and dietary supplements, which are substances added in trace amounts to compound feed to supplement components that are prone to being deficient when only natural feed ingredients are mixed, or to improve the shelf life of the feed, but are not limited thereto.
[0046] The feed additive composition according to the present invention can be prepared by adding one or more selected from the group consisting of ppGpp (Guanosine 5'-diphosphate 3'-diphosphate) deficient variant enteropathogenic E. coli (EPEC), lysed products thereof, and cultures of said strains, in an appropriate effective concentration range according to various feed manufacturing methods known in the art.
[0047] The feed additive according to the present invention can be applied without limitation to any individual intended for the prevention or improvement of muscle loss, muscle atrophy, or muscle weakness. For example, it can be applied to any individual, such as non-human animals like monkeys, dogs, cats, rabbits, guinea pigs, rats, mice, cattle, sheep, pigs, goats, etc., as well as birds and fish.
[0048]
[0049] According to an aspect of the present invention, the present invention provides a pharmaceutical composition for the prevention or treatment of diseases caused by muscle weakness, muscle loss, or muscle atrophy, comprising the strain Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.
[0050] In a specific embodiment of the present invention, the disease resulting from muscle weakness, muscle loss, or muscle atrophy is preferably one or more selected from the group consisting of sarcopenia, atony, muscular atrophy, muscular dystrophy, muscle degeneration, myotonic dystrophy, amyotrophic lateral sclerosis, myasthenia, and cachexia, and is applicable without limitation to any symptom, disease, or illness caused by muscle weakness, muscle loss, or muscle atrophy.
[0051] In the present invention, prevention refers to any act of suppressing or delaying the onset of a disease caused by muscle weakness, muscle loss, or muscle atrophy through the administration of a pharmaceutical composition according to the present invention. Furthermore, in the present invention, treatment refers to any act of improving or beneficially altering the symptoms of a disease caused by muscle weakness, muscle loss, or muscle atrophy through the administration of a pharmaceutical composition according to the present invention.
[0052] The pharmaceutical composition of the present invention may further include pharmaceutically acceptable additives, wherein the pharmaceutically acceptable additives may include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, lactose, mannitol, malt syrup, gum arabic, pregelatinized starch, corn starch, powdered cellulose, hydroxypropyl cellulose, Opadry, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, aluminum stearate, calcium stearate, sucrose, etc. The pharmaceutically acceptable additive according to the present invention is preferably included in an amount of 0.1 to 90 parts by weight with respect to the composition, but is not limited thereto.
[0053] In addition, the pharmaceutical composition of the present invention may be administered in various oral or parenteral formulations during actual clinical administration. When formulating, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants, and it is preferable to use suitable formulations known in the art. Carriers, excipients, and diluents that may be included in the composition include lactose, dextrose, sucrose, oligosaccharides, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil, etc.
[0054] The above-mentioned solid dosage forms for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid dosage forms are prepared by mixing at least one excipient, such as starch, calcium carbonate, sucrose or lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Furthermore, the above-mentioned liquid dosage forms for oral administration include suspensions, liquid formulations, emulsions, syrups, etc., and may include various excipients, such as humectants, sweeteners, flavorings, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin.
[0055] The above-mentioned preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspension solvents. Witepsol, Macrogol, Tween 61, cacao oil, laurin oil, glycerogelatin, etc. may be used as bases for suppositories. The above-mentioned parenteral administration may be performed using external application to the skin or by intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, or intrathoracic injection.
[0056] The dosage of the pharmaceutical composition of the present invention varies depending on the patient's weight, age, gender, health condition, diet, time of administration, method of administration, excretion rate, and severity of the disease, and may be administered once a day or divided into several doses.
[0057] The pharmaceutical composition of the present invention can be administered to an individual via various routes.
[0058] The pharmaceutical composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy, and biological response modifiers for the prevention or treatment of diseases caused by muscle weakness, muscle loss, or muscle atrophy.
[0059]
[0060] According to another aspect of the present invention, the present invention provides a composition for muscle enhancement; or for muscle strength enhancement comprising the strain Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.
[0061] In the present invention, the muscle enhancement and strength strengthening are preferably achieved through the promotion of muscle cell differentiation, inhibition of muscle cell death, improvement of muscle strength, improvement of exercise performance, or an increase in the body's mineral content.
[0062] In an embodiment of the present invention, the strain according to the present invention was orally administered to mice. As a result, the muscle and body mineral content of the mice were significantly increased, and the hip-shin muscle mass increased by up to 29% compared to before administration. In addition, in another embodiment of the present invention, when the strain according to the present invention was orally administered to aged mice, it was confirmed that grip strength and treadmill performance ability increased significantly. The above results indicate that the strain according to the present invention positively alters body composition and improves exercise ability, and thus can be utilized as a composition for muscle augmentation or strength enhancement.
[0063] The composition for muscle enhancement or muscle strength strengthening of the present invention can be manufactured in various forms such as food compositions, health functional food compositions, and food additive compositions, and can be used as an adjuvant for muscle growth and strength strengthening in the general public as well as for muscle loss caused by aging or disease.
[0064]
[0065] According to another aspect of the present invention, the present invention provides a method for preventing or treating a disease caused by muscle weakness, muscle loss, or muscle atrophy, comprising the step of administering the strain of Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof to an individual in need thereof.
[0066] The above-mentioned strain of Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), its culture medium, its concentrate, its lysate, its dried form, or a combination thereof may be administered to individuals requiring it in a therapeutically effective amount. Preferably, the individuals are mammals, including humans, and include both patients who have received prevention or treatment for diseases caused by muscle loss, muscle atrophy, or muscle atrophy, and patients who need to receive prevention or treatment for diseases caused by muscle loss, muscle atrophy, or muscle atrophy, and may also include patients who have undergone other therapies or treatments for the prevention or treatment of diseases caused by muscle loss, muscle atrophy, or muscle atrophy.
[0067] Furthermore, the present invention may be used in combination with existing drugs or treatment methods for the prevention or treatment of diseases caused by muscle loss, muscle atrophy, or muscle weakness. When the present invention is used in combination, it may be used simultaneously or sequentially with other drugs or treatment methods for the prevention or treatment of diseases caused by muscle loss, muscle weakness, or muscle atrophy.
[0068]
[0069] According to another aspect of the present invention, the present invention provides the use of the Lactiplantibacillus plantarum MTY101 strain (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof for the manufacture of a drug for the prevention or treatment of diseases caused by muscle weakness, muscle loss, or muscle atrophy.
[0070]
[0071] Redundant content is omitted out of consideration for the complexity of this specification, and terms not otherwise defined in this specification have the meanings commonly used in the technical field to which this invention belongs.
[0072] The present invention will be described in more detail below through examples. These examples are solely for illustrating the present invention, and it will be obvious to those skilled in the art that the scope of the present invention is not to be interpreted as being limited by these examples.
[0073]
[0074] Example 1. Selection and Characterization of Lactic Acid Bacteria Strains Promoting Muscle Differentiation and Formation
[0075] Lactiplantibacillus plantarum MTY101, which has activity promoting muscle differentiation and formation, was selected from a library of lactic acid bacteria cultures. The inventors deposited the above Lactiplantibacillus plantarum MTY101 with the Biological Resource Center (Jeongeup-si, Jeollabuk-do, Korea) on March 19, 2025, in accordance with the Treaty of Budapest, and were assigned accession number KCTC15786BP.
[0076] 1-1. Genome-based analysis of the MTY101 strain
[0077] The phylogenetic tree and ANI were analyzed based on the whole genome of the MTY101 strain isolated from kimchi and are shown in Figure 1. It was confirmed that the MTY101 strain of the present invention has a 3.34 Gb genome analyzed into 47 contigs and possesses 3,173 genes. These genes include 3,101 CDS, 63 tRNAs, 8 rRNAs, and 1 tmRNA.
[0078]
[0079] 1-2. Antibiotic susceptibility of MTY101 strain
[0080] The antibiotic susceptibility of Lactiplantibacillus plantarum MTY101 was evaluated using minimum inhibitory concentration (MIC) test strips (KisanBio, Korea). The antibiotic susceptibility of the strain to eight antimicrobial agents, including ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, and tetracycline, was tested according to the guidelines of the European Food Safety Authority (EFSA). Specifically, cells were aerobically cultured in MRS medium at 37°C for 18 hours, harvested by centrifugation at 11,000 rpm for 5 minutes, and washed three times with PBS (pH 7.4). The washed cells were resuspended in PBS at McFarland Standard 0.5. The cell suspension was inoculated onto BHI agar containing cotton swabs. The plates were dried for 10–15 minutes, and MIC test strips were placed on the agar surface. Next, after incubating the plates at 37°C for 48 hours, the MIC was read based on the intersection of the MIC scale on the test strip and the elliptical area of growth inhibition. Cutoff values for various antibiotics were evaluated according to EFSA guidelines. The results of evaluating antibiotic resistance using MIC and hemolysis tests are shown in Table 1.
[0081] As a result of antibiotic susceptibility testing, it was confirmed that the bacteria were susceptible to most antibiotics, but showed resistance to ampicillin (AM) and chloramphenicol (CL) and inherent resistance to vancomycin (VM). In particular, it was confirmed that bacterial growth was inhibited at a minimum inhibitory concentration (MIC) for erythromycin (EM) that was more than half lower than the cut-off value.
[0082] Strain nameStrainAntimicrobial susceptibility (MIC) (μg / mL)AMVMGMKMSMEMCMTCCLCut-off values2n.r.1664n.r.12328L.plantarumMYT1013>0.532320.1251.51612
[0083] * nr not required; Ampicillin (AM); Vancomycin (VM); Gentamicin (GM); Kanamycin (KM); Streptomycin (SM); Erythromycin (EM); Clindamycin (CM); Tetracycline (TC); Chloramphenicol (CL)
[0084]
[0085] 1-3. Muscle differentiation and formation-promoting activity of MTY101 strain
[0086] C2C12 mouse myoblasts 1 x 10 4 Cells were mixed with culture medium (DMEM, 10% FBS, 1% AA), seeded into 96-well plates, and cultured in an incubator for 24 hours. After 24 hours, YY1-promoter-gaussia luciferase DNA (pYY1-Gluc, 50 ng) and Flag-PHF20 DNA (200 ng) were introduced into the cells using Lipofectamine 3000 (cat# L3000001, Invitrogen) according to the manufacturer's manual. 24 hours after introduction, the culture medium was replaced with fresh medium, and 1 x 10⁶ 8CFU of Lactobacillus plantarum MTY101 culture medium (CFU) was added to the cell culture medium at a concentration of 2% and cultured for an additional 24 hours. After the culture was completed, the activity of Gaucia luciferase was measured. The Gaucia luciferase activity was measured using a dedicated reagent (cat#LF062, Genecopenia), and the experiment was performed according to the manufacturer's manual. In addition, the control groups for this experiment were YY1-promoter-Gaucia luciferase without culture medium treatment, and YY1-promoter-Gaucia luciferase+PHF20. As a comparative experimental group, the culture mediums of nine other Lactobacillus plantarum strains distributed by the Korea Research Institute of Biotechnology and Bioengineering were treated in the same manner, and the YY1 promoter activity was compared. The results of the YY1 promoter activity measurement are shown in Figure 2. The graph shows the mean and standard deviation of the three repeated measurements of each sample, and the difference between samples was tested using the two-sample t-test (independent samples t-test) in Excel statistics (***p <0.001).
[0087] As shown in Figure 2, the MTY101 lactic acid bacteria culture significantly inhibited YY1 transcriptional activation induced by PHF20 (P<0.001). In addition, the MTY101 strain exhibited excellent YY1 promoter inhibitory activity compared to other Lactiplantibacillus plantarum strains, whereas the nine Lactiplantibacillus plantarum strains used as a comparative group showed no YY1 promoter inhibitory activity at all.
[0088] Accordingly, the Lactibacillus plantarum MTY101 strain of the present invention was selected as a strain having excellent muscle differentiation and formation-promoting activity, and the strain of the present invention and its culture medium were used in additional experiments below.
[0089]
[0090] Example 2. Identification of biomarkers related to muscle differentiation promotion and muscle degradation inhibition following treatment with strain culture medium
[0091] 2-1. Dexamethasone-induced muscular atrophy C2C12-cell model
[0092] C2C12 myoblasts were seeded into 6-well plates and cultured in the medium until the plates were more than 90% full; subsequently, the medium was changed to myotube differentiation medium (DMEM, 2% Horse Serum, 1% AA) to induce myotube differentiation. Differentiation was carried out for 5 days, with the medium being replaced daily. To induce muscle atrophy, 100 μM dexamethasone (DEX) was administered at day 4, at which point 1 x 10⁶ 8 CFU of MTY101 lactic acid bacteria culture was simultaneously treated according to the concentrations indicated in each province. After 24 hours of dexamethasone treatment, the medium was removed and the cells were harvested by washing once with PBS.
[0093]
[0094] 2-2. Protein Expression Analysis
[0095] The above intracellular protein extraction is performed using a protein extraction solution (PRO-PREP TMProteins were extracted using Protein Extraction Solution (iNtRON) according to the manufacturer's protocol, and then separated using 12–15% SDS-PAGE. The separated proteins were then transferred to a PVDF membrane and immersed in 5% skim milk / TBS-T (0.05% Tween-20) for 1 hour at room temperature to block the membrane. Subsequently, Western blotting was performed using the following antibodies: Abcam's Atrogin-1 (#ab92281), Cell Signaling Technology's p-AKT (#4060) and AKT (#9272), Santa Cruz's GAPDH (sc-25778), and Sigma Aldrich's β-actin (#A2228). GAPDH and β-actin were used as internal controls to correct for total protein amounts between samples. The results of the protein expression analysis are shown in Figure 3.
[0096] As shown in Figure 3a, it was confirmed that the expression of the muscle degradation biomarker Atrogin-1, which was increased by dexamethasone treatment, decreased in a concentration-dependent manner with the treatment of MTY101 lactic acid bacteria culture. Conversely, it was confirmed that the phosphorylation of the muscle synthesis biomarker AKT, which was reduced by dexamethasone treatment, was inhibited by treatment with MTY101 lactic acid bacteria culture.
[0097]
[0098] 2-3. mRNA Expression Analysis
[0099] RNA isolation, cDNA synthesis, and Q-PCR samples were prepared using the AccuPrep® Universal RNA Extraction Kit, AccuPower® RT PreMix, and AccuPower® 2X GreenStar® qPCR MasterMix (Bioneer, Korea), respectively, according to the respective manufacturers' protocols. PCR reactions were performed using an AriaMx real-time PCR instrument (Agilent) under the following conditions: 1) initial denaturation step, 3 min at 95°C, 2) denaturation step, 15 sec at 95°C, 3) annealing step, 30 sec at 60°C, 4) extension step, 30 sec at 72°C, and steps 2) through 4) were carried out for 40 cycles.
[0100] The primer sequences used for PCR are as follows: mouse GAPDH, forward: 5'-TCCAGTATGACTCCACTC-3' (Sequence No. 1), reverse: 5'-ATTTCTCGTGGTTCACAC-3' (Sequence No. 2); mouse Atrogin-1, forward: 5'-AACCGGGAGGCCAGCTAAAGAACA' (Sequence No. 3), reverse: 5'-TGGGCCTACAGAACAGACAGTGC-3' (Sequence No. 4); mouse MuRF-1: forward: 5'-GAGAACCTGGAGAAGCAGCT' (Sequence No. 5), reverse: 5'-CCGCGGTTGGTCCAGTAG-3' (Sequence No. 6).
[0101] mRNA expression of each gene is adjusted to the control gene GAPDH expression level, 2 -ΔΔCt It was calculated using the method and displayed as a graph of the mean and standard deviation (n=3 / sample).
[0102] As shown in Figure 3b, it was confirmed that the mRNA expression of the muscle degradation biomarkers Atrogin-1 and MuRF-1 was increased by dexamethasone treatment (***p<0.001). This increase induced by dexamethasone was inhibited by treatment with MTY101 lactic acid bacteria culture (***p<0.001).
[0103]
[0104] Example 3. Confirmation of cytotoxicity and apoptosis inhibitory efficacy of strain culture medium
[0105] 1x10 4 of C2C12 cells were seeded into a 96-well plate and cultured in culture medium for 24 hours. After 24 hours, the medium was replaced with fresh medium, and 1 x 10⁶ 8 CFU of MTY101 lactic acid bacteria culture was treated at concentrations of 0.25–5% and cultured for 24 hours. After 24 hours, cell viability was measured using an MTT assay (Ez-Cytox, cat#EZ-3000, DoGenBio). The results are shown in Figure 4a (mean + standard deviation, n=3 / sample).
[0106] As shown in Figure 4a, the MTY101 lactic acid bacteria culture showed cell viability similar to the control group at all treatment concentrations, confirming that it was not cytotoxic.
[0107] To determine whether MTY101 lactic acid bacteria culture medium inhibits dexamethasone-induced apoptosis in myotube cells, 1x10 8 CFU of MTY101 lactic acid bacteria cultures were co-treated with dexamethasone at concentrations of 0.25–1% and cultured in differentiation medium for 24 hours. Apoptosis was measured by the MTT assay, and the results are shown in Figure 4b (mean + standard deviation, n=3 / sample).
[0108] As shown in Figure 4b, the decrease in cell viability induced by dexamethasone (*p<0.05) was inhibited in a manner dependent on the treatment concentration of MTY101 lactic acid bacteria culture (*p<0.05, **p<0.01).
[0109]
[0110] Example 4. Effect of MTY101 Lactic Acid Bacteria Culture Solution on Promoting Myotube Formation
[0111] In this example, the myotube formation-promoting effect of the MTY101 lactic acid bacteria culture solution was confirmed. Specifically, sterile glass coverslips were placed in a 24-well plate, and 5 x 10 per well 4 C2C12 cells were seeded and cultured in culture medium for 24 hours. After 24 hours, the medium was changed to differentiation medium and differentiated for 3 days. During the differentiation period, 1 x 10⁶ 8 CFU of MTY101 lactic acid bacteria culture was added to the differentiation medium at a concentration of 1%, and the differentiation medium was changed daily. After differentiation was complete, the cells were washed twice with PBS and fixed in 4% paraformaldehyde for 15 minutes at room temperature. Then, they were washed three times with PBS and incubated in 0.2% Triton x-100 / PBS for 10 minutes at room temperature, followed by washing three times with PBS and blocking the cells in 1% BSA / PBS for 1 hour at room temperature. Subsequently, the anti-MYH antibody (Santacruz, sc-376157) was diluted 1:1000 in 1% BSA and incubated with the cells at 4°C for 24 hours, followed by washing three times with PBS and Alexa Fluor TM Plus 488-second antibody (Invitrogen, Cat # A32723: 1:5000, diluted with PBS) was reacted for 1 hour at room temperature under light-blocked conditions. Fluorescently stained myotube cells were stained for cell nuclei using DAPI VECTASHIELD (St. Louis, USA), and after mounting the coverslips on glass slides, images were taken using a Zeiss fluorescence microscope. The results of the fluorescence staining are shown in Figure 5.
[0112] As shown in Figure 5, it was confirmed that root canal formation was promoted in the group treated with MTY101 lactic acid bacteria culture compared to the untreated group.
[0113]
[0114] Example 5. Efficacy of MTY101 Lactobacillus (Live Bacteria) in Improving Grip Strength in a Dexamethasone Muscle Atrophy Mouse Model
[0115] 5-1. Dexamethasone-induced muscular atrophy mouse model
[0116] After acclimatizing 7-week-old male C57BL / 6N mice in the rearing room for 1 week, the mice were randomly divided into Control, DEX, and MTY101 groups (n=5 / group). Muscle atrophy was induced in the DEX and MTY101 groups by daily intraperitoneal injection of dexamethasone (25 mg / kg) for 9 days. Subsequently, the Control and DEX groups were administered PBS, while the MTY101 group was administered 1x10 8 CFU of MTY101 live bacteria were suspended in 100 µl of PBS and orally administered daily for 14 days. Grip strength was measured on days 12 and 23 after dexamethasone administration, and body weight was measured periodically (on days 0, 2, 4, 6, 11, 19, and 24). Body composition was analyzed using dual-energy x-ray absorptiometry (DXA) on day 11 (before administration of the test substance) and day 24 (after administration of the test substance). Then, on the following day, day 25, the mice were euthanized, and tissue from the tibialis anterior (TA) muscle of the hind leg was isolated.
[0117]
[0118] 5-2. Grip Strength Evaluation
[0119] Changes in mouse body weight and grip strength evaluation results during the test period are shown in Figures 6a and 6b, respectively (mean + standard error, n=5 mice / group).
[0120] As shown in Figure 6a, on the 11th day of dexamethasone administration, it was confirmed that the body weight of the dexamethasone administration groups (DEX group and MTY101 group) decreased compared to the control group (*p<0.05). This weight loss indicates that a muscle atrophy model induced by dexamethasone has been established. Subsequently, this weight loss returned to the level of the control group.
[0121] As shown in Figure 6b, on the 12th day, the day after the end of dexamethasone administration, it was confirmed that the grip strength of the groups administered dexamethasone (DEX group and MTY101 group) was significantly reduced compared to the control group (*P<0.05). Then, when grip strength was measured on the 23rd day, the grip strength of the MTY101 group recovered to the level of the control group (**P<0.01), but the grip strength of the DEX group was confirmed to be significantly reduced compared to the control group (**P<0.01). This indicates that the decrease in grip strength caused by dexamethasone administration is inhibited by the administration of MTY101 lactic acid bacteria (live bacteria).
[0122]
[0123] Example 6. Efficacy of MTY101 Lactobacillus (Live Bacteria) in Improving Muscle Mass
[0124] 6-1. Increase in Muscle Mass Following Administration of MTY101 Probiotics (Live Bacteria)
[0125] To confirm the effect of administering MTY101 probiotics (live bacteria) on muscle mass increase, changes in muscle mass before and after the administration of the test substance were confirmed through body composition analysis using DXA after the administration of MTY101 probiotics (live bacteria) was completed in the same manner as in Example 5. The results of measuring total muscle mass, right hind leg muscle mass, and right hind leg muscle mass before and after administration in dexamethasone-induced muscle atrophy mice after the administration of Lactibacillus plantarum MTY101 probiotics (live bacteria) are shown in Figures 7a to 7c, respectively.
[0126] As shown in Figures 7a and 7b, there was no significant difference in total muscle mass between groups after the end of administration. On the other hand, when comparing the muscle mass of the right hind leg, it was confirmed that the muscle mass of the DEX group was significantly reduced compared to the control group (*P<0.05). Furthermore, this decrease in hind leg muscle mass caused by dexamethasone was found to be inhibited by the administration of MTY101 (*P<0.05).
[0127] As shown in Figure 7c, this figure illustrates the change in right hind leg muscle mass before and after the administration of the test substance to each group. The control group showed an increase in muscle mass with increasing age (**P<0.01), but the DEX group did not show an increase in muscle mass. On the other hand, the MTY101 group showed a significant increase in muscle mass after administration compared to before administration, despite the administration of dexamethasone (**P<0.01).
[0128]
[0129] 6-2. Increase in Muscle Cross-sectional Area Following Administration of MTY101 Probiotics (Live Bacteria)
[0130] In the same manner as in Example 5, hindlimb tibial muscle tissues from dexamethasone-induced muscular atrophy mice administered MTY101 lactic acid bacteria (live bacteria) were fixed with 4% paraformaldehyde at 4°C for 48 hours and then embedded in paraffin to produce paraffin blocks. The paraffin blocks were sliced to a thickness of 4 μm and stained with hematoxylin and eosin (H&E). H&E images were captured using a microscope (EVOSTM M5000, Invitrogen), and the muscle cross-sectional area was analyzed using Image J software. The results of observing the stained sections are shown in Fig. 7d, and the graph based on this is shown in Fig. 7e (mean + standard error, n=5 / group).
[0131] As shown in Figures 7d and 7e, it was confirmed that the muscle cross-sectional area of the DEX group was significantly reduced compared to the control group (*P<0.05). And it was confirmed that the muscle cross-sectional area of the MTY101 group was significantly increased compared to the DEX group (*P<0.05). This indicates that muscle reduction caused by dexamethasone is inhibited by the administration of MTY101 probiotics (live bacteria).
[0132]
[0133] Example 7. Statistical Analysis
[0134] Differences between samples were tested using the paired t-test or unpaired t-test in Excel statistics, with *; P-value (reliability) <0.05, **; p<0.01, ***; p<0.001. P<0.05 was interpreted as a statistically significant difference. Cases where there was no statistically significant difference were indicated as ns.
[0135]
[0136] In summary, the inventors selected a strain of the genus Lactobacillus that promotes muscle differentiation and formation. Furthermore, experiments confirmed that the selected strain of the genus Lactobacillus not only has no cytotoxicity but also inhibits muscle degradation while simultaneously promoting muscle synthesis. Therefore, the strain of the genus Lactobacillus of the present invention can be utilized in various fields related to the treatment of muscle loss diseases and muscle growth.
[0137]
[0138] Foregoing, specific parts of the present invention have been described in detail. It will be apparent to those skilled in the art that such specific descriptions are merely preferred embodiments and do not limit the scope of the invention. Accordingly, the actual scope of the invention is defined by the appended claims and their equivalents.
[0139] Deposit of biological materials
[0140] Lactibacillus plantarum MTY101 of the present invention was deposited with the Biological Resource Center (Jeongeup-si, Jeollabuk-do, Korea) on March 19, 2025, in accordance with the Treaty of Budapest, and was assigned accession number KCTC15786BP.
[0141] If the patent is granted, all restrictions on the public use of the deposited culture are irrevocably lifted, and the applicant retains the right to request that a request for the deposit be made in accordance with 37 CFR §1.808(b).
[0142] The deposit will be kept for 30 years from the date of deposit or 5 years from the date of the last sample request or for the longer of the patent term, and will be maintained with all necessary care to keep it viable and uncontaminated in any case.
[0143] The applicant requests that, for all designated and / or elected countries, and to the extent legally permissible under the laws of such countries, the samples of biological material deposited in this application be made available only to independent experts in accordance with applicable patent laws, e.g., Rule 32 of the European Patent Convention (EPC), Rule 13(1) and Sections 6 and 7 of the UK Patent Rule 2007 (Revised), and similar provisions applicable to other designated countries.
[0144]
Claims
1. A food composition for the prevention or improvement of muscle strength and muscle loss; or muscle atrophy comprising the strain Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.
2. The strain of claim 1 is a composition having one or more activities selected from the group consisting of promoting differentiation of muscle cells, inhibiting apoptosis of muscle cells, improving muscle strength, improving exercise performance, and increasing mineral content in the body.
3. A food composition according to claim 1, wherein the prevention or improvement of muscle strength and muscle reduction; or muscle atrophy is muscle strengthening, muscle strength improvement, muscle augmentation, promotion of muscle differentiation, or muscle regeneration.
4. A health functional food composition for the prevention or improvement of muscle strength and muscle loss; or muscle atrophy, comprising the strain Lactiplantibacillus plantarum MTY101 (Accession No.: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.
5. A pharmaceutical composition for the prevention or treatment of diseases caused by muscle strength and muscle loss; or muscle atrophy, comprising the strain Lactiplantibacillus plantarum MTY101 (Accession No.: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.
6. A composition according to claim 5, wherein the muscle strength and muscle loss; or the disease resulting from muscle atrophy is one or more selected from the group consisting of sarcopenia, atony, muscular atrophy, muscular dystrophy, muscle degeneration, myotonic dystrophy, amyotrophic lateral sclerosis, myasthenia, and cachexia.
7. A feed composition for the prevention or improvement of muscle strength and muscle loss; or muscle atrophy comprising the strain Lactiplantibacillus plantarum MTY101 (Accession No.: KCTC15786BP), its culture medium, its concentrate, its lysate, its dried form, or a combination thereof.
8. A composition for muscle strengthening and muscle enhancement comprising the strain Lactiplantibacillus plantarum MTY101 (Accession No.: KCTC15786BP), the culture medium thereof, the concentrate thereof, the lysate thereof, the dried product thereof, or a combination thereof.
9. A method for preventing or treating muscle strength and muscle loss; or a disease caused by muscle atrophy, comprising the step of administering the strain of Lactiplantibacillus plantarum MTY101 (accession number: KCTC15786BP), its culture medium, its concentrate, its lysate, its dried form, or a combination thereof to an individual in need thereof.
10. Use of the strain Lactiplantibacillus plantarum MTY101 (Accession No.: KCTC15786BP), its culture medium, its concentrate, its lysate, its dried form, or a combination thereof, for the manufacture of a drug for the prevention or treatment of diseases caused by muscle weakness and muscle loss; or muscle atrophy.
